Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 | Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.
DelveInsight’s, “Triple Negative Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Triple Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Triple Negative Breast Cancer Pipeline Report
- DelveInsight’s Triple Negative Breast Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline treatment therapies.
- The leading Triple Negative Breast Cancer Companies working in the market include Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
- Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.
- November 2023: Shanghai Jiaolian Drug Research and Development Co., Ltd announced a study of Phase 2 & 3 clinical trials for B013+Nab-Paclitaxel. This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
- November 2023: Gilead Sciences announced a study of Phase 3 clinical trials for Pembrolizumab. The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician’s choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
- November 2023: AstraZeneca announced a study of Phase 1 & 2 clinical trials for Datopotamab Deruxtecan (Dato-DXd). This is a Phase 1/Phase 2, multicentre, open-label, multiple-cohort study, which is designed to evaluate the efficacy, safety, Pharmacokinetic, and immunogenicity of Dato-DXd in adult Chinese participants with advanced or metastatic solid tumours. It is a single-arm study with no blinding.
- On June 2023, Shanghai Jiaolian Drug Research and Development Co., Ltd announced a study of phase 2 & 3 clinical trials for B013+Nab-Paclitaxel. This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
- On February 2023, Jina Pharmaceuticals announced a study of phase 3 clinical trials for Taxotere® (100 mg/m2). The trial will be conducted as per the ICH GCP Guidelines E6 (R1), Schedule Y (Amended Version 2013), Declaration of Helsinki (Fortaleza, Brazil, October 2013), ICMR Guidelines for Biomedical Research on Human subjects and in accordance with other applicable guidelines.
Request a sample and discover the recent advances in Triple Negative Breast Cancer Treatment Drugs @ Triple Negative Breast Cancer Infection Pipeline Report
In the Triple Negative Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Triple Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Triple Negative Breast Cancer Overview
Triple Negative Breast Cancer (TNBC) is defined as a tumor where the estrogen and progesterone (ER/PR) are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers.
Find out more about Triple Negative Breast Cancer Treatment Landscape @ Drugs for Triple Negative Breast Cancer Treatment
Triple Negative Breast Cancer Emerging Drugs Profile
- Camrelizumab: Jiangsu HengRui Medicine
- IPI-549: Infinity Pharmaceuticals
- PMD-026: Phoenix Molecular Designs
Triple Negative Breast Cancer Pipeline Therapeutics Assessment
There are approx. 75+ key companies which are developing the therapies for Triple Negative Breast Cancer. The Triple Negative Breast Cancer companies which have their Triple Negative Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Jiangsu HengRui Medicine.
DelveInsight’s Triple Negative Breast Cancer pipeline report covers around 80+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
Triple Negative Breast Cancer Pipeline Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Learn more about the emerging Triple Negative Breast Cancer Pipeline Therapies @ Triple Negative Breast Cancer Clinical Trials Assessment
Scope of the Triple Negative Breast Cancer Pipeline Report
- Coverage- Global
- Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Triple Negative Breast Cancer Companies- Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
- Triple Negative Breast Cancer Pipeline Therapies- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.
Dive deep into rich insights for new drugs for Triple Negative Breast Cancer treatment, Visit @ Triple Negative Breast Cancer Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Triple Negative Breast Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Triple Negative Breast Cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Camrelizumab: Jiangsu HengRui Medicine
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- IPI-549: Infinity Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- PMD-026: Phoenix Molecular Designs
- Drug profiles in the detailed report…..
- Inactive Products
- Triple Negative Breast Cancer Key Companies
- Triple Negative Breast Cancer Key Products
- Triple Negative Breast Cancer- Unmet Needs
- Triple Negative Breast Cancer- Market Drivers and Barriers
- Triple Negative Breast Cancer- Future Perspectives and Conclusion
- Triple Negative Breast Cancer Analyst Views
- Triple Negative Breast Cancer Key Companies
- Appendix
For further information on the Triple Negative Breast Cancer pipeline therapeutics, reach out @ Triple Negative Breast Cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/oral-electrolyte-solutions-market
